Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MVD | P53602 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202635 | 0.79 | MEN1 (0.57) | MEN1KMT2ATDP1ALDH1A1CYP3A4 | |
| SCHEMBL10696687 | 0.76 | MEN1 (0.48) | MEN1KMT2ATDP1ALDH1A1CYP3A4 | |
| SCHEMBL2180857 | 0.75 | ALDH1A1 (0.47) | MEN1KMT2ATDP1ALDH1A1CYP3A4 | |
| SCHEMBL1202631 | 0.75 | ALDH1A1 (0.47) | MEN1KMT2ATDP1ALDH1A1CYP3A4 | |
| SCHEMBL1973590 | 0.75 | — | — | |
| SCHEMBL4300681 | 0.74 | ALDH1A1 (0.41) | ALDH1A1CYP3A4HSD17B10TSHR | |
| SCHEMBL2180860 | 0.74 | MEN1 (0.61) | MEN1KMT2ATDP1ALDH1A1CYP3A4 | |
| SCHEMBL24909869 | 0.74 | LPAR3 (0.33) | TDP1ALDH1A1HSD17B10LPAR3LPAR2 | |
| SCHEMBL11446189 | 0.72 | MEN1 (0.70) | MEN1KMT2ATDP1ALDH1A1CYP3A4 | |
| SCHEMBL483082 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | disclosed |
| US-20100041077-A1 | PESTICIDE BIOMARKER | ATERIS TECHNOLOGIES, LLC | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | MEN1 3248/4885KMT2A 1669/4885TDP1 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.